Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert
This article was originally published in The Pink Sheet Daily
Executive Summary
Pooled analyses of data on COPD treatment show increased risk of stroke in two patients per 1,000, agency says.
You may also be interested in...
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.
Spiriva May Be UPLIFTed By Positive Trial Results After JAMA Bashing
BI, Pfizer rebut assertion inhaled anticholinergics carry cardio risk.